Breaking Finance News

ValuEngine downgraded Pernix Therapeutics Holdings Inc (NASDAQ:PTX) to Strong Sell in a report released today.

Only yesterday Pernix Therapeutics Holdings Inc (NASDAQ:PTX) traded -7.84% lower at $3.85. PTX’s 50-day average is $3.69 and its two hundred day average is $3.81. With the last stock price close up -35.20% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same time. 304,343 shares of PTX traded hands, up from an average trading volume of 231,467

ValuEngine has downgraded Pernix Therapeutics Holdings Inc (NASDAQ:PTX) to Strong Sell in a statement released on 7/8/2017.

On 3/08/2016, Needham released a statement on Pernix Therapeutics Holdings Inc (NASDAQ:PTX) reduced the target price from $10.00 to $8.00 that suggested an upside of 2.33%.

Recent Performance Chart

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

With a total market value of $0, Pernix Therapeutics Holdings Inc has 52 week low of $0.40 and a 52 week high of $7.15 .

A total of 4 equity analysts have released a ratings update on PTX. 3 firms rating the stock a strong buy, 1 analyst rating the company a buy, zero analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally 0 brokerages rating the company a sell with a 12-month price target of $7.00.

General Company Details For Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *